Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00003789
Other study ID # NCI-2012-01843
Secondary ID Z0020ACOSOG-Z002
Status Completed
Phase Phase 3
First received November 1, 1999
Last updated July 15, 2013
Start date March 1999

Study information

Verified date June 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Heating melphalan to several degrees above body temperature and infusing it only to the area around the tumor may kill more tumor cells. It is not yet known whether combining melphalan with tumor necrosis factor is more effective than melphalan alone in treating melanoma.


Description:

OBJECTIVES:

I. Compare hyperthermic isolated limb perfusion with melphalan with or without tumor necrosis factor, in terms of response proportion for lesions in the perfusion field, in patients with locally advanced extremity melanoma.

II. Compare the local recurrence-free survival, improvement in regional symptoms related to tumor, and overall survival in patients treated with these regimens.

III. Compare the toxicity of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor burden (high vs low), prior reperfusion (melphalan vs other), regional nodal site (yes vs no), and participating center. Patients are randomized to one of two treatment arms.

ARM I: Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.

ARM II: Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.

Patients are followed within 6 weeks, at 3, 6, and 12 months, every 6 months for 4 years, and then annually thereafter.


Other known NCT identifiers
  • NCT00056732

Recruitment information / eligibility

Status Completed
Enrollment 216
Est. completion date
Est. primary completion date January 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically proven locally advanced melanoma of an extremity

- One or more evaluable in-transit metastases

- All disease within the perfusion field of the extremity (with no local resection options short of amputation)

- Disease outside of perfusion field (with no local resection options short of amputation) if all the following are true:

- High tumor burden (more than 10 lesions or any single lesion greater than 3 cm)

- Presence of pain, edema, skin breakdown, or decreased mobility

- Greater than 80% of known tumor is within extremity perfusion field

- Life expectancy more than 6 months

- No brain metastases

- At least 1 bidimensionally measurable lesion

- Patients who received prior prophylactic isolated limb perfusion (ILP) must have 1 of the following:

- Disease-free interval for at least 6 months after prior ILP with melphalan

- Disease-free interval for at least 3 months after prior ILP with an agent other than melphalan

- Patients who received prior therapeutic ILP must have 1 of the following:

- Partial response of at least 3 months duration after prior ILP with melphalan

- Stable response or disease progression after ILP without melphalan (performed at least 3 months prior to study)

- Performance status - ECOG 0-2

- Performance status - Zubrod 0-2

- See Disease Characteristics

- Platelet count at least 100,000/mm^3

- WBC greater than 2,500/mm^3

- Hemoglobin greater than 9 g/dL

- Bilirubin less than 1.25 times ULN

- AST and ALT less than 2 times ULN

- Alkaline phosphatase less than 2 times ULN

- Coagulation studies normal or within 1 second of upper limit of normal (ULN)

- Creatinine less than 1.5 mg/dL

- Creatinine clearance greater than 50 mL/min

- Calcium less than 12 mg/dL

- No severe peripheral vascular disease (claudication or other ischemic peripheral vascular disease [e.g., venous thrombosis or occlusive peripheral arterial disease])

- No New York Heart Association class II-IV heart disease (congestive heart failure)

- No uncontrolled or life-threatening cardiac arrhythmia

- No myocardial infarction within the past year

- No unstable angina

- No symptomatic cerebral or carotid artery disease

- No pulmonary embolism within the past year

- Other prior malignancy allowed if completed curative therapy, disease-free for at least 5 years, and at low risk for recurrence

- No active peptic ulcer disease within the past year

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No known melphalan hypersensitivity

- No known hypersensitivity to any component of tumor necrosis factor alpha formulation

- No contraindications to ionotropic agents (e.g., dopamine or neosynephrine)

- No concurrent infections uncontrolled with antibiotics

- HIV negative

- At least 1 month since prior biologic therapy

- See Disease Characteristics

- At least 1 month since prior chemotherapy

- At least 4 months since prior isolated limb perfusion

- At least 1 month since prior radiotherapy

- See Disease Characteristics

- At least 12 months since prior coronary artery surgery or angioplasty

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
isolated limb perfusion
Undergo isolated limb perfusion
melphalan
Given via limb perfusion
Biological:
recombinant tumor necrosis factor family protein
Given via slow injection into the arterial line
Other:
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States American College of Surgeons Oncology Group Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary CR proportion Response will be calculated based on the 3-month follow-up assessment of presence of absence of complete response. This will be done using the logistic regression model. Up to 3 months after completion of study treatment No
Primary Incidence of adverse events, graded according to NCI CTC version 2.0 The quantification and between-arm comparison of toxicity will be studied. Up to 1 month after completion of study treatment Yes
Secondary Local progression-free survival Time to event outcome models will be based on proportional hazard regression. Up to 12 years No
Secondary Overall survival Time to event models will be based on proportional hazard regression. Up to 12 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02224781 - Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Phase 3
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT01886235 - Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery N/A
Completed NCT00553306 - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma Phase 1/Phase 2
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Completed NCT00019448 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT01961115 - Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Phase 2
Completed NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Early Phase 1
Terminated NCT01316692 - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma Phase 2
Active, not recruiting NCT01120275 - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Terminated NCT01166126 - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Phase 2
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00288041 - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00074308 - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Phase 1/Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT01989559 - Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery Phase 1
Completed NCT00026143 - Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Phase 2
Completed NCT00006243 - Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma N/A
Active, not recruiting NCT04284774 - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2